- Home
- CRBP vs ZURA Comparison
CRBP vs ZURA Comparison
Compare CRBP & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- ZURA
- Stock Information
- Founded
- CRBP 2009
- ZURA 2022
- Country
- CRBP United States
- ZURA United States
- Employees
- CRBP N/A
- ZURA N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRBP Health Care
- ZURA Health Care
- Exchange
- CRBP Nasdaq
- ZURA Nasdaq
- Market Cap
- CRBP 73.4M
- ZURA 61.9M
- IPO Year
- CRBP N/A
- ZURA N/A
- Fundamental
- Price
- CRBP $8.33
- ZURA $1.13
- Analyst Decision
- CRBP Strong Buy
- ZURA Buy
- Analyst Count
- CRBP 10
- ZURA 7
- Target Price
- CRBP $53.56
- ZURA $14.33
- AVG Volume (30 Days)
- CRBP 123.5K
- ZURA 545.9K
- Earning Date
- CRBP 08-05-2025
- ZURA 08-08-2025
- Dividend Yield
- CRBP N/A
- ZURA N/A
- EPS Growth
- CRBP N/A
- ZURA N/A
- EPS
- CRBP N/A
- ZURA N/A
- Revenue
- CRBP N/A
- ZURA N/A
- Revenue This Year
- CRBP N/A
- ZURA N/A
- Revenue Next Year
- CRBP $150.03
- ZURA N/A
- P/E Ratio
- CRBP N/A
- ZURA N/A
- Revenue Growth
- CRBP N/A
- ZURA N/A
- 52 Week Low
- CRBP $4.64
- ZURA $0.97
- 52 Week High
- CRBP $61.90
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- CRBP 54.09
- ZURA 45.37
- Support Level
- CRBP $8.10
- ZURA $1.10
- Resistance Level
- CRBP $9.45
- ZURA $1.37
- Average True Range (ATR)
- CRBP 0.52
- ZURA 0.09
- MACD
- CRBP -0.08
- ZURA 0.00
- Stochastic Oscillator
- CRBP 55.74
- ZURA 37.18
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.